Vanguard Portfolio Management’s Prime Medicine PRME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.55M Buy
961,826
+99,622
+12% +$331K ﹤0.01% 2540
2026
Q1
$3M Buy
+862,204
New +$3.28M ﹤0.01% 2478

Other funds holding PRME

Vanguard Portfolio Management's PRME Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Prime Medicine (PRME) stake by 12% in Q2 2026, buying an estimated $331K and bringing the position to 961,826 shares worth $3.55M. The position accounts for ﹤0.01% of the portfolio, ranked #2540.

Vanguard Portfolio Management first reported a position in PRME in Q1 2026 and has held it in 2 quarters since. 186 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Vanguard Portfolio Management held 961,826 shares of Prime Medicine worth $3.55M as of Q2 2026.
  • Vanguard Portfolio Management bought 99,622 Prime Medicine shares in Q2 2026, an estimated $331K.
  • Prime Medicine made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2540 holding.
  • Vanguard Portfolio Management first reported a position in Prime Medicine in Q1 2026 and has held it in 2 quarters since.
  • 186 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.